Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilhelm Huisinga

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Cancers|June 2, 2021
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical GroupsAnna Mueller-Schoell, Robin Michelet, Lena Klopp-Schulze, et al.
Clinical Pharmacokinetics|August 1, 2025
Author's Reply to Helsby and Hannam: 'Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights'Ayatallah Saleh, Josefine Schulz, Jan-Frederik Schlender, et al.
British Journal of Anaesthesia|February 2, 2025
Evaluation of the need for dosing adaptations in obese patients for surgical antibiotic prophylaxis: a model-based analysis of cefazolin pharmacokineticsDavide Bindellini, Philipp Simon, David Busse, et al.
Pharmaceuticals (Basel, Switzerland)|February 6, 2021
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing StrategiesAnna Mueller-Schoell, Lena Klopp-Schulze, Robin Michelet, et al.
Clinical Pharmacokinetics|October 30, 2024
Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical InsightsAyatallah Saleh, Josefine Schulz, Jan-Frederik Schlender, et al.
Cancers|July 2, 2021
Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology ModelAnna Mueller-Schoell, Nahum Puebla-Osorio, Robin Michelet, et al.
Pharmaceutics|September 28, 2021
Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid PharmacokineticsDavid Busse, Philipp Simon, David Petroff, et al.
European Journal of Clinical Pharmacology|December 15, 2020
Correction to: Therapeutic drug monitoring of oral targeted antineoplastic drugsAnna Mueller-Schoell, Stefanie L Groenland, Oliver Scherf-Clavel, et al.
Pharmaceutics|October 27, 2022
Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive ReviewAlix Démaris, Ella S K Widigson, Johan F K F Ilvemark, et al.
European Journal of Endocrinology|July 5, 2020
Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young childrenRobin Michelet, Johanna Melin, Zinnia P Parra-Guillen, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Cancers|June 2, 2021
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical GroupsAnna Mueller-Schoell, Robin Michelet, Lena Klopp-Schulze, et al.
Clinical Pharmacokinetics|August 1, 2025
Author's Reply to Helsby and Hannam: 'Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights'Ayatallah Saleh, Josefine Schulz, Jan-Frederik Schlender, et al.
British Journal of Anaesthesia|February 2, 2025
Evaluation of the need for dosing adaptations in obese patients for surgical antibiotic prophylaxis: a model-based analysis of cefazolin pharmacokineticsDavide Bindellini, Philipp Simon, David Busse, et al.
Pharmaceuticals (Basel, Switzerland)|February 6, 2021
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing StrategiesAnna Mueller-Schoell, Lena Klopp-Schulze, Robin Michelet, et al.
Clinical Pharmacokinetics|October 30, 2024
Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical InsightsAyatallah Saleh, Josefine Schulz, Jan-Frederik Schlender, et al.
Cancers|July 2, 2021
Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology ModelAnna Mueller-Schoell, Nahum Puebla-Osorio, Robin Michelet, et al.
Pharmaceutics|September 28, 2021
Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid PharmacokineticsDavid Busse, Philipp Simon, David Petroff, et al.
European Journal of Clinical Pharmacology|December 15, 2020
Correction to: Therapeutic drug monitoring of oral targeted antineoplastic drugsAnna Mueller-Schoell, Stefanie L Groenland, Oliver Scherf-Clavel, et al.
Pharmaceutics|October 27, 2022
Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive ReviewAlix Démaris, Ella S K Widigson, Johan F K F Ilvemark, et al.
European Journal of Endocrinology|July 5, 2020
Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young childrenRobin Michelet, Johanna Melin, Zinnia P Parra-Guillen, et al.
Pageof 9